Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GNI And EpiCept Ink Development Deal For Anti-Viral Hepatitis B Drug

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - GNI and EpiCept have entered into an agreement that will see the latter develop a new anti-viral hepatitis B drug, EP1013, in Asia, Australia and New Zealand

You may also be interested in...



China’s Biopharma Sector Enjoys 20% Growth

Western partners underestimate resources needed to establish quality processes, understand mind-sets in Chinese industry, thought leader says.

China’s Biopharma Sector Enjoys 20% Growth

Western partners underestimate resources needed to establish quality processes, understand mind-sets in Chinese industry, thought leader says.

China’s Biopharma Sector To Grow At 20 Percent - Study

SHANGHAI - The Chinese biopharmaceutical sector continues to grow by 20 percent each year, according to a study published in August by BioPlan Associates and the Society for Industrial Microbiology

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel